Some purchases by bullish investors boosted the valuation in recent months, ahead of Neuralink's May 25 announcement that U.S. regulators had approved a human trial on its brain chip, the sources said.
The stock transactions at a valuation of around $5 billion have been carried out by shareholders such as employees and the company's early backers, rather than Neuralink selling new shares to investors. Such so-called secondary trades are an imperfect gauge of a company's value; their volume is thin and they lack the wider market consensus of a fundraising round or initial public offering .
Many of the recent stock sales have been to relatively small investors, who typically focus more on getting a slice of a company owned by Musk than scrutinizing its valuation. The maximum amount sought for the Neuralink shares marketed for sale at a $7 billion valuation was just $500,000, according to the email seen by Reuters.
"A study to assess safety and tolerability is in no shape or form valid to justify a $5 billion valuation," said Sridhar, who helped launch Galvani Bioelectronics, a developer of implants backed by GSK Plc and Alphabet Inc's Verily Life Sciences. Galvani is not a competitor of Neuralink because its implants under development will be installed in an artery to the spleen to help treat rheumatoid arthritis, rather than the brain.
Switzerland Neuesten Nachrichten, Switzerland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Herkunft: globeandmail - 🏆 5. / 92 Weiterlesen »